Araujo-Mino EP, et al. - Researchers conducted a trial combining chemoradiation and cyclooxygenase-2 (COX-2) inhibition to assess the pathologic complete response rate, surgical outcomes, survival, and treatment toxicity. In rectal cancer, chemoradiation with celecoxib was well tolerated and demonstrated high rates of pathologic complete response, surgical downstaging, and sphincter-sparing surgery. Addition of celecoxib to neoadjuvant chemotherapy was associated with significant improvement in skin toxicity (34% grade 1 and no grade 3/4) as compared with historical results (43%–78% grade 3/4).